MCRB

Seres Therapeutics (MCRB)

About Seres Therapeutics (MCRB)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Details

Daily high

$16.62

Daily low

$15.90

Price at open

$16.00

52 Week High

$29.98

52 Week Low

$6.53

Market cap

143.8M

Dividend yield

0.00%

Volume

52,878

Avg. volume

301,941

P/E ratio

26.19

Seres Therapeutics News